rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MLYS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Mineralys Therapeutics stock hits 52-week low at 14.89 USD
      Nov 13Investing.comMLYS
      Mineralys at Stifel 2026 Healthcare Conference: launch focus builds
      Nov 12Investing.comMLYSSF
      Mineralys at Guggenheim healthcare conference: launch prep in focus
      Nov 10Investing.comMLYS
      Why is Mineralys Therapeutics stock climbing today?
      Nov 9Investing.comMLYS
      Mineralys stock gains after drug shows sustained blood pressure cuts
      Nov 9Investing.comMLYS
      Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on November 3, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award coveri

      Nov 6Yahoo FinanceMLYS
      Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade)
      Nov 5Seeking AlphaMLYS
      Mineralys Therapeutics Inc (MLYS) Q3 2026 Earnings Call Highlights: Strong Phase 3 Data and ...

      Mineralys Therapeutics Inc (MLYS) showcased robust lorundrostat efficacy and advanced commercial preparations while reporting a widened net loss ahead of its December PDUFA date.

      Nov 5Yahoo FinanceMLYS
      Mineralys Therapeutics (MLYS) Publishes Lorundrostat CKD Data, Is The Stock Still A Bargain?

      Lorundrostat’s Phase 2 Explore-CKD data is now in a top kidney journal, giving Mineralys Therapeutics (MLYS) a clearer clinical story focused on blood pressure and urinary protein reductions in chronic kidney disease patients. Despite the Kidney International publication and a series of lorundrostat updates, Mineralys Therapeutics’ share price return has been weak, with the stock down 52.39% year to date and 37.01% over 90 days. At the same time, a very large 3 year total shareholder return...

      Nov 5Yahoo FinanceMLYS
      What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call
      Nov 5Yahoo FinanceMLYS
      Mineralys Therapeutics Q3 2026 Earnings Call Transcript
      Nov 4BenzingaMLYS
      Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
      Nov 4Yahoo FinanceMLYS
      Mineralys earnings on deck as FDA decision on lorundrostat looms
      Nov 4Investing.comMLYS
      How InvestingPro’s Fair Value flagged Mineralys stock before 50% drop By Investing.com
      Nov 4Investing.comMLYS
      Mineralys Therapeutics to Participate in Upcoming Investor Conferences
      Nov 3Yahoo FinanceMLYS
      Kidney Trial Results Could Change The Case For Mineralys Therapeutics Stock
      Nov 1Yahoo FinanceMLYS
      Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
      Oct 28Yahoo FinanceMLYS
      Mineralys reports positive phase 2 CKD trial results
      Oct 28Investing.comMLYS
      Mineralys Therapeutics director Slingsby sells $3.0 million in shares
      Oct 27Investing.comMLYS
      Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
      Oct 22Yahoo FinanceMLYS
      Mineralys appoints two directors ahead of drug launch
      Oct 19Investing.comMLYS
      Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
      Oct 19Yahoo FinanceMLYS
      Mineralys Therapeutics stock hits 52-week low at 20.4 USD
      Oct 16Investing.comMLYS
      Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Palvella Therapeutics (PVLA) and Mineralys Therapeutics, Inc. (MLYS)

      Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailMLYSPVLAPFE
      Mineralys Therapeutics CEO Jon Congleton sells $1.9m MLYS stock
      Oct 13Investing.comMLYS
      Mineralys Therapeutics (MLYS) Shares New Lorundrostat Data, Is The Stock A Bargain?
      Oct 12Yahoo FinanceMLYS
      UBS Initiates a Hold Rating on Mineralys Therapeutics, Inc. (MLYS)

      Detailed price information for Mineralys Therapeutics Inc (MLYS-Q) from The Globe and Mail including charting and trades.

      Oct 12The Globe and MailMLYS
      H.C. Wainwright reiterates Mineralys stock rating on new data
      Oct 12Investing.comMLYS
      UBS initiates Mineralys Therapeutics stock with neutral rating
      Oct 12Investing.comMLYS
      Mineralys Therapeutics, Inc. (MLYS) Presents at American Heart Association Hypertension Scientific Sessions 2026 - Slideshow (NASDAQ:MLYS) 2026-10-09

      2026-10-09. The following slide deck was published by Mineralys Therapeutics, Inc.

      Oct 9Seeking AlphaMLYS
      Mineralys Therapeutics stock hits 52-week low at 22.23 USD
      Oct 6Investing.comMLYS
      Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
      Oct 2Yahoo FinanceMLYS
      Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
      Oct 1Yahoo FinanceMLYS
      Mineralys at Stifel cardiometabolic forum: launch plan takes shape
      Sep 30Investing.comMLYSSF
      Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
      Sep 29Yahoo FinanceMLYS
      Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat Data

      Why the latest lorundrostat data matters for Mineralys Therapeutics investors Mineralys Therapeutics (MLYS) is back on watch after the company flagged that long term efficacy and safety results from its Transform-HTN extension study of lorundrostat will feature in a late breaking session at the American Heart Association Scientific Sessions 2026. The latest lorundrostat update comes after a choppy stretch for Mineralys Therapeutics, with the share price falling 8.65% over the past week and...

      Sep 28Yahoo FinanceMLYS
      Mineralys Therapeutics director sells $3 million in shares
      Sep 25Investing.comMLYS
      Mineralys to present lorundrostat trial data at AHA meeting
      Sep 23Investing.comMLYS
      Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
      Sep 23Yahoo FinanceMLYS
      Mineralys Therapeutics CCO Eric Warren sells $209k in stock
      Sep 23Investing.comMLYS
      Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      RADNOR, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 21, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award cov

      Sep 21Yahoo FinanceMLYS
      Mineralys Therapeutics director Karydas sells $85,740 in stock
      Sep 17Investing.comMLYS
      Mineralys at Wells Fargo conference: lorundrostat launch takes shape
      Sep 9Investing.comMLYSWFC
      Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 8, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards coveri

      Sep 9Yahoo FinanceMLYS
      Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision (MLYS)
      Sep 3Seeking AlphaMLYS
      Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

      RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines...

      Aug 26BarchartMLYS
      Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares
      Aug 25Investing.comMLYS

      This is the newest page. Registered accounts read further back.